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Background	  
Monoclonal antibodies targeting B-cells has become one of the most promising 
options in the treatment of autoimmune diseases. In multiple sclerosis (MS), 
rituximab (RTX) has been evaluated in two phase II studies. While RTX showed 
beneficial effects in relapsing-remitting (RR) MS, the study of primary progressive 
(PP) MS was negative. Yet, a subgroup analysis revealed lower rate of progression in 
younger patients with ≥1 contrast enhancing lesion on MRI (Magnetic Resonance 
Imaging). RTX is not approved for MS, but the off-label use has over recent years 
increased in Sweden and comprises 19,2% (May 2015) of all MS treatments. 
 
Objectives	  
To evaluate the reason for use, efficacy, safety and tolerability of RTX treatment in 
MS. 
	  
Method	  
In this retrospective study we searched the Swedish MS register (SMSreg) and 
treatment registers for MS patients treated with RTX between 2008 to 2014. We 
identified 105 patients; 41 RRMS, 41 secondary progressive (SP) MS and 23 PPMS. 
Data were extracted from the SMSreg and medical chart review. RTX was initiated 
with 2 infusions of 1000 mg, 2 weeks apart, and then as single infusions at 6 months 
intervals.  
 
Results	   
Reasons for switching to RTX varied from one to several combined causes. In RRMS 
patients (n=41) the reason was treatment failure on other disease modifying therapies 
(DMTs, 56%), JC virus antibody (JCV+) in natalizumab treated patients (34%), 
adverse events (AE) from previous DMT (Disease Modifying Treatment)(20%), and 
neutralizing antibodies (NAB) against interferon beta or nataluzimab (7%). The 
corresponding reasons for RTX in the PMS group (n=64, both SPMS and PPMS) was 
disease activity and progression (90%), JCV+ (12%), AE (6%) and NAB (3%). 
Comparing the number of patients having “relapses the last two years” and “relapses 
after RTX start” shows a reduction in both the RRMS patients (from 36.6% to 9.8%) 
and PMS patients (from 21.8% to 7.8%).  
 
RTX median treatment time was 13 (3-74) months. During RTX treatment of RRMS 
and PMS the median expanded disability status scale (EDSS) increased (+0.5, range 
0-8.0 and +0.5, range 1.5-8.5, respectively), median multiple sclerosis severity scale 
(MSSS) decreased (-0.66, range 0.86-9.94 and -0.19, range 1.43-9.95, respectively). 
However the MSSS-score did not show statistical significance, p=0.077. Infusion 
related reactions was 49.5% at first infusion, 13.3% at 2nd infusion, and 9.5% at 3rd 
RTX infusion. No severe AE was recorded. 
 
16 patients stopped RTX treatment; 6 due to AE, 4 due to treatment failure and 6 of 
unknown reasons. 
Conclusions	  
RTX was used as treatment primarily as a last line of treatment after having disease 
activity in previous treatments. RTX was well tolerated with no severe AE. RTX had 
no obvious effect on EDSS progression but decreased relapse rate and MSSS which 
could indicate a beneficial effect in both RRMS and PMS. 
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Introduction	  	  
According to the Swedish MS Association there are approximately 17000 people with 
Multiple Sclerosis (MS) in Sweden today. [1] Sweden has one of the highest 
prevalence and incidence in the world and MS is the main non-traumatic cause of 
neurological disability among young adults. [2]  
 
There is no curative treatment for MS today, but there are several disease modifying 
therapies (DMT) available, all of which primarily target the immune process either 
unspecific or associated to T-cell function (e.g. dimeylfumarate, teriflunomide, 
fingolimod, nataluzimab, interferon-beta and glatirameracetate).[3, 4] These therapies 
can only in part affect the disease in RRMS, and has not showed any significant effect 
in the progressive stage of MS. [5-7]  
 
The role of the B-cell in the disease process of MS has been explored the last decade 
and is now believed to play a key role in MS, as the B-cell takes part in multiple 
stages in the inflammatory activation, through antibody production, T-cell activation 
and the release of cytokines.  
  
In line with these theories the chimeric monoclonal antibody, rituximab (RTX) has 
been tested and examined as a possible treatment against MS. RTX was originally 
manufactured for diseases with a B-cell-associated pathogenicity, such as Hodgkins 
Lymphoma and Rheumatoid Arthritis (RA). RTX targets hocytes expressing the 
CD20-antigen, which is expressed on B-cells and induces cell death in the entire 
germline, with exception for the plasma cells. [8-10]  
 
In multiple sclerosis (MS) RTX has been evaluated in two phase II studies. 
In these studies a beneficial effect was shown in relapsing-remitting (RR) MS, but 
showed no positive effect in primary progressive (PP) MS. However, a subgroup 
analysis discovered lower rate of progression in patients of younger age, ≤51years and 
with ≥1 contrast enhancing lesion on MRI.[7] 
  
 
Figure 1. Treatment dispersion across Sweden in percentages and county. Rituximab = Mabthera – here 
represented in turquoise.  [11] 
 
There is an extensive use of RTX, off label, against MS in all regions of Sweden and 
comprises a total of 19.2% of all MS treatments in the country. In Gothenburg RTX 
has been used since 2008 with a steady increase. [1] 
 
Why remains to be explained as well as to evaluate outcomes for these patients.  
In order to correctly examine and evaluate important aspects of patients being treated 
with RTX we performed a retrospective study of all patients diagnosed with RRMS, 
PPMS and SPMS treated with Mabthera (Rituximab) between 2008 and early 2015 in 
the city of Gothenburg, Sweden.  
 
Epidemiology/Aetiology	  	   	  
Alike the other Scandinavian countries, Sweden has one of the highest MS prevalence 
in the world, with a prevalence of 189/100000 and with an estimated incidence of 
circa 10/100000. (Ahlgren et al.) Today there are approximately 17500 registered 
patient with MS in Sweden. In MS there is a 2.35 ratio between women and men with 
a more then double risk for women compared to men. The risk ratio is less obvious in 
PPMS. [2] Disease onset is most common around the age of 20-40.  
 
There is a correlation between latitude and risk of developing MS, in other words the 
risk of MS increases the farther from the equator one lives. [12] There are also 
theories correlating the lack of sun exposure and therefore lower levels of vitamin-D 
with MS, which in turn can be associated with geographical distribution. [13] 
Being a smoker or living with a smoker seems to have a worsening impact on risk and 
prognosis of MS. [14-17] 
 
It is believed that being infected by EBV at a young age increases the risk of 
developing MS. [18] Some studies even show that elevations in antiEBV-antibody 
titers occur prior to the MS-debut and that this is a sign of early MS. [19] 
The theory is strengthened by the fact that people who migrate from high to low risk 
regions during childhood have a decreased risk profile and vice versa. [20] [21]  
 Clinical	  Course	  of	  MS	  	  	  
The clinical onset of multiple sclerosis is in 85% of cases preceded by a clinically 
isolated syndrome (CIS), an acute or sub-acute neurological disturbance due to white-
matter lesions. [22] If in addition CIS is accompanied by abnormalities in unaffected 
white matter the risk of a second attack is high. With a secondary relapse the 
McDonald-criteria (see Diagnostic Criteria) for the diagnosis MS are met.[23, 24] 
 
Onset of disease may be abrupt or insidious. The severity of onset symptoms varies 
within a wide range, from trivial to severe. [25] The most common disease course is 
relapsing-remitting MS (RRMS), and is represented in 85% of patients in the initial 
stage of disease. An average of 65% of patients with RRMS enter the progressive 
phase of MS (SPMS). This usually occurs within 10-15 years (in an untreated 
population).  For around 10-15% of patients the course is progressive from start, then 
called primary progressive (PPMS). This progressive course of disease is 
characterized by less evident inflammation and a more gradual worsening of 
symptoms without obvious fluctuations or discernible relapses. [23, 26, 27]  
 
Initial symptoms of MS may have mono- or multifocal basis and symptoms are 
dependent on location of the lesions in the central nervous system (CNS). Even 
though location of the lesions are to some extent random they more frequently involve 
certain areas including the optic nerve (optic neuritis, 25%), the spinal cord (40%) or 
the brain stem (25%). Other early symptoms are weakness, sensory disturbance such 
as diminished tactility, diplopia, gait instability, and ataxia. [25, 26] 
 
In RRMS there is possibility of a complete or partial recovery from symptoms is 
possible. Relapses usually last weeks to months. With time the symptoms persist and 
accumulate. Typical symptoms of progressive MS (PMS) consist of over months to 
years development of spastic para- or tetraparesis, cerebellar ataxia, spastic 
hemiparesis. Disability also manifests through symptoms such as bladder dysfunction, 
fatigue, heat sensitivity, Lhermitte’s symptom (electric sensory sensation down the 
spine evoked by neck flexion), hemifacial weakness or pain, vertigo, tonic spasms and 
other paroxysmal symptoms, add to the complex disease progress.  
Approximately 50% of untreated patients will eventually become dependent of a 
wheel chair 30 years after diagnosis. [28, 29] 
 
Cognitive and neurophysiological deficits (e.g. memory loss, attention disorders, 
slowed problem solving), accompany the disease especially in advanced cases. [30, 
31] Depression is expressed by around 60% of patients and therefore the suicide risk 
is 7.5-fold more common. [25] 
Patients diagnosed with MS are usually expected to have a reduction in life 
expectancy of up to 5-10 years, with an additional risk of committing suicide as 
mentioned. Death is attributable to MS in 2/3 of cases, where the patients 
susceptibility to infections is increased.[32-34] 
 
	  
Diagnostic	  Criteria	  in	  MS	  	  
As MS has a wide spectrum of phenotypes and clinical appearances diagnosis is not 
always easy to establish. A fast and precise diagnosis is essential in an era with a 
plethora of DMT’s preventing neurological disability.  
 The core criterion in diagnosing MS has long been to establish evidence of 
dissemination in time (DIT) and in space (DIS) between, at least, two white matter 
inflammations in the CNS, that have objective clinical evidence. [35]  
 
The McDonald criteria help establish ground rules on how these diagnostic 
parameters should be accounted for.  
The principal goal is to simplify the MS diagnostic criteria without compromising in 
sensitivity and specificity, and so since its acknowledgement the McDonald criteria 
has been modified and revised twice. [35-37] These improvements have resulted in 
the possibility of earlier diagnosis and therefore also earlier interventions and/or 
treatments. [38, 39] 
In struggle to deliver a fast diagnosis it is vital to consider and reject alternative 
diagnosis, as e.g. neuromyelitis optica (NMO). These diseases often resemble MS but 
treatments generally have no or less effect.   
 
In the McDonald criteria latest revision PPMS criteria is now included and requires 
one year of disease progression and two of the following three findings: positive brain 
MRI; positive spinal cord MRI; or positive CSF. [35] 
It is not evident to see the transition between RRMS and SPMS since relapses and 
exacerbations can leave remaining disabilities and also superimpose. However the 
SPMS diagnosis is coupled with unremitting worsening for at least six months.  
 
	  Measurements	  of	  disease	  activity	  and	  progression	  	  	  
Disease activity is best measured in clinical manifestations and everyday 
functionality.  In addition, ta prognostic score is available to show what is to expect in 
terms of worsening and amelioration. 
 
Expanded Disability Status Scale, EDSS 
Ever since J.F.Kurtzke introduced the Expanded Disability Status Scale (EDSS) in 
1983 it’s been the golden standard when it comes to rating disease disability in 
clinical routine.  
The EDSS evaluates seven functional systems (FS) and ambulatory abilities, through 
a standardized set of neurological tests. The scale ranges from 0 to 10.  
The FS consider: 
• Pyramidal motor functions  
• Cerebellar function 
• Brainstem  
• Sensory abilities  
• Bowel and bladder  
• Visual  
• Cerebral or mental   
• Motor function 
 
Zero constitutes a normal neurological examination. A score of 1.0 to 3.5 represents 
people with some FS symptoms but with complete ambulatory capabilities. 4.0 until 
6.5 include people with ambulatory restrictions. A score more than 6.5 will mainly 
incorporate patients in need of assistance or even wheelchair. Score 10 means death 
caused by MS.[40, 41]     
 
Multiple Sclerosis Severity Scale, MSSS 
In comparison to EDSS the MSSS aims towards predicting disability progression in 
MS. The EDSS development over the course of MS in 9892 patients from eleven 
countries helped establish a general disease progression rate, plotted into a 
standardized matrix. By inserting the EDSS and the duration of disease in each axis of 
the matrix one can find its MSSS-score, 0.01 to 9.99.  
Though the MSSS is based on a large population some question if it is applicable on 
todays population influenced by modern therapies.  
 
Magnetic Resonance Imaging - MRI 
During the last decade, the radiologic magnetic resonance imaging (MRI) has become 
an important tool in measuring therapeutic efficacy, disease activity and progression 
of MS.  
By “weighting” MRI-images, adjusting properties, it is possible to acquire distinctive 
information when it comes to pathological severity, presence of blood brain barrier 
damage, BBB-damage, or to visualizing disease expansion.  
MRI also has predictive capabilities in that the number of lesions found at disease 
onset may predict the disability development. [42] 
 
Clinical evaluation together with MRI, make up the diagnostic foundation for MS and 
have made other paraclinical tools such as biochemical biomarkers and 
neurophysiological examinations less significant.  [36, 43-45] The latest revision of 
the MRI criteria (MAGNIMS) allows MS diagnosis after one clinical episode in 
addition to signs of activity on one MRI (with Gadolinium enhancing lesions).[46] 
However MRI cannot be used as an evaluation tool of the pathophysiological 
developments nor is it optimal for evaluating the PMS progression as changes in brain 
tissue is not as evident in this form of MS.  
 
Genes  
The familial recurrence rate in MS is around 20%, but the heredity is complex. More 
than 50 risk genes have been identified. The genotype called “HLA class II genotype 
DRB1*15:03”, carried by 28-33% of northern Caucasian MS patients versus 9-15% 
of healthy controls has the strongest association of all genes.[47] Risk reducing genes 
have also been found. Most genes are located in or in close proximity of the immune-
regulating genes. Most genes have association with other autoimmune diseases. [48, 
49] 
 
B-­‐cell	  	  
Over the last couple of years several studies have targeted the B-cell to be a key 
component in MS. [50] The humoral immune system and the B-cell involvement has 
been known for decades but has been regarded as less important for the process . 
However, recently this matter has been subject for further investigation, as the T-cell 
branch of the immune system no longer is believed to be sufficient for full expression 
of MS. [8, 51]  
The B-cell may play a key role in MS, here follows some evidence of such a 
postulations: Histopathological studies that have shown presence of b-cell, b-cell 
derived plasma cells and antibodies in active and chronic plaques in patients 
diagnosed with MS.[52] The intrathecal IgG synthesis is consistent with B-cell 
expansion.[53] The presence of markers of B-cell activity, such as (nonpathogenic 
myelin basic protein), B-cell chemokines (CXCL 13) and antibodies.[54] The 
discovery of the B-cells fundamental role in the induction of the animal equivalent to 
MS, experimental autoimmune encephalomyelitis (EAE). [55]  
 
As implied B-cells have not been the main target of elimination in therapeutic 
treatments, “until now”. But established treatments have unintentionally displayed 
anti B-cell action through several coherent mechanisms, e.g. (a) interferon-beta 
inhibits antibody secretion through anti-CD40/80 effect.[56-58]  
(b) Glatiramer acetate is known to inhibit antigen-presenting cells (APC), including 
B-cells. [59] (c) Antiproliferative medications such as Mitoxantrone affects the total 
number of B-cells and their cytokine production. [60] (d) Through the mechanism of 
altering the APCs capabilities Corticosteroids affect the immunoglobulin synthesis. 
[61, 62]And finally (e) Nataluzimab alters the expression of very late antigen 4(VLA-
4), which is expressed on and responsible for the B-cells transmigration brain 
endothelial sites.[63]  
 
As mentioned earlier the EBV may be implicated in triggering the autoimmunity in 
MS, furthermore the EBV mainly hibernates in B-lymphocytes.  
 
The role(s) played by B-cells, plasma cells, and antibodies in CNS inflammatory 
demyelinating diseases are likely to be multifactorial and complex, involving distinct 
and perhaps opposing roles for B cells versus antibody. [3]  
 
Rituximab	  	  
The Food and Drug Administration (FDA, USA) in 1997 first approved RTX for use 
against B-cell Lymphomas and later treatment resistant Rheumatoid Arthritis. 
However RTX has been used for several years as an off-label treatment against other 
autoantibody-mediated diseases.[64]    
RTX is a genetically engineered chimeric IgG monoclonal antibody. It targets B-
lymphocytes in all development stages, with exception for the plasma cell, through 
the trans-membrane antigen CD20. The Fab domain of the monoclonal antibody binds 
the CD20 antigene of the B-cell. The antibody then induces cytotoxicity through 
apoptosis or complement-dependent cytotoxicity, resulting in lysis. [8, 9, 65]  
The depletion of the B-lymphocytes will affect development of new antibody 
producing cells, all B-cell mediated, antigene presentation, activation and propagation 
of T-cells, macrophages and cytokine networks.  [4]  
 
In the phase II trial OLYMPUS, Hawker and co-workers investigated RTX in 
treatment of MS. They discovered no significant effect in their primary end point, 
“time to confirmed disease progression” (CDP), but patients had an overall 
diminished lesion progression in all subjects. Further and foremost new evidence for 
the usage towards a subgroup of patients, patients aged ≤51years old was found, were 
subjects in the subgroup had an increased time to CDP and a reduction in gadolinium-
enhanced lesions. 
 
Questions have been raised against the effectiveness of RTX since the B-cell 
activation and IgG-synthesis is intrathecal, but its been shown that RTX penetrates the 
CNS, through an intact blood brain barrier (BBB). [66] 
 The usage of RTX has a positive risk profile since the drug has long documentation of 
AE’s on treatment against RA. [67] Several studies mostly show mild to moderate 
AE’s. [7] [68] The most common AE’s documented are itching of skin and throat, 
flushing, chills, fever and/or diarrhea.[68, 69] 
 
Contraindications for treatment with RTX is know immune-deficiency syndrome due 
to immune-suppressive treatment, on going pregnancy and breast-feeding.    
Antibody production against RTX is documented and quite common, in some cases 
with frequencies around 30-40%. However these antibodies are usually none-
neutralizing and do not affect the intended treatment.  
No significance was been shown in studies when testing the increased risk of common 
infections whilst being under anti-CD20 antibody treatments. Progressive Multifocal 
Leukoencephalopathy (PML) has previously been mentioned in correlation with 
Mabthera (Rituximab) treatments but none in the field of neurology under indications 
of MS.[70] 
 
In using RTX it is expected that B-cells play an important role in the pathogenesis of 
multiple sclerosis and links having an abnormal B-cell activation to T-cell mediated 
immunopathology. In fact increasing evidence show that antibodies may play a role in 
the initiation of plaques and the demyelination process in MS. [64]  
 
 
 
Indications 
The usage of RTX is still quite arbitrary in the neurological field and in MS, but there 
does exist local indications. In RRMS, RTX can be introduced when there is evidence 
of either clinical or radiological activity whilst being under treatment of a more 
established immunomodulating treatment (beta-interferon, glatriameracetat, 
fingolimod, nataluzimab, mitoxantrone). [71] 
In PPMS and SPMS, indications of inflammatory activity either noted through 
clinical relapses or by new MRI lesions. [72] 	  
Aims	  The	  purpose	  of	  this	  study	  is	  to	  evaluate	  reasons	  for	  using	  of	  RTX,	  its	  efficacy,	  saftey	  and	  tolerability	  among	  patients	  with	  MS.	  	  
Method/Materials	  	  
Demographics	  	  
All patients had been diagnosed according to the McDonald’s Criteria [1] with sub-
groups RRMS, PPMS or SPMS. [73] All individuals started treatment between 2008 
and early 2015. 
All patients treated with RTX, on the indication MS, at the MS-Center, Sahlgrenska 
University Hospital were included. 105 patients were selected after discarding 
patients with NMO, patients with inconclusive diagnosis and patients lacking 
essential data. 
Demographic data shown in Table 2. RRMS 41 patients (39%), SPMS also 41 
patients (39%) and PPMS 23 patients (21.9%), figure 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-3.To the left - demographics gender distribution in the group and age. 
To the right - Disease form representation, shown in percentage. RRMS, SPMS and PPMS.  	   	   	   	   	   	  
Clinical	  Assessments	  	  	  
All patients were treated with RTX in accordance with guidelines established at the 
MS-Center  (The Department of Clinical Neuroscience and Rehabilitation) 
Sahlgrenska University Hospital, Gothenburg – Mabthera (Rituximab) – treatment of 
Multiple Sclerosis.[71] These guidelines are mainly based on the OLYMPUS phase II 
study by Hawker et al. [7]  
 
1. RRMS-patients – Initial treatment dose consists of 2 infusions a 1000mg x2 
with 14 days apart. Thereafter infusions every 6 month a 1000mg during a 
period of 3 years. After which an annual infusion is made if no signs of 
disease progression, usually evaluated through MRI. 
   
2. PPMS and SPMS-patients - Same dosage as for RRMS-patients but with 
evaluations after 3 years.  After 3 years patients will only be subject to 
infusions if new progression is shown. MRI-evaluations after 3-6 months and 
then each 12 months.    
 
Patients who underwent the Mabthera (Rituximab) treatment were also subjects to 
testing prior and after treatment. See Table 1.  
 
Table 1. Un extract from the Mabthera treatment protocol showing tests taking prior and during 
Rituximab treatment.  
Tests/Control	   Prior	  to	  treatment	   Each	  6	  months	   Annually	  
Blood/Differential	  Count	  
and	  IgG	  
YES	   YES	   	  
Immunophenotyping	  and	  
B-­‐lymphocyte	  count	  (%)	  
	  
YES	  
	   	  
YES	  
Pregnancy	  testing	  	   Before	  each	  
infusion	  
	   	  
	  
Collected	  Data	  	  	  
The patient data and information was collected through the VGR (Västra Götalands 
Regions) administrative system – Melior and through the “Swedish National Multiple 
Sclerosis Register”. Two separate data extraction dates were put in place, 01/08/14 
and 01/02/15.   
The following parameters were recorded for each individual:  
• Age  • Sex 
• MS-type • Start & stop dates of treatment 
• Reasons for treatment change  • Number of doses received  
• EDSS-scores one year before 
RTX at start and at data extraction 
date  
• MSSS-scores at start and at data 
extraction date 
• New MRI-lesions • Reoccurrence of B-cells 
• Relapse rate the last two years and 
after RTX start  
• Adverse events  
 
 
The MS-debut and diagnose dates for each patient was collected as well as dates for 
the transition to SPMS for concerned parties. Emphasis was put on the MS-debut, 
which was based on first symptom presentation.  
 
The reasons for change to Rituximab from other treatment were categorized in 
following groups:  -­‐ Treatment refractivity of other treatments  -­‐ Neutralizing antibodies (NAB) against the previously given medication  -­‐ Adverse effects against previously given medication -­‐ Disease progression in general.  -­‐ JCV-positive or PML patients -­‐ No other treatment is available – all other possibilities had been considered  -­‐ Other – patients whom for special reasons changed to Rituximab.  
 
RRMS patient- and PMS patient (SPMS and PPMS together) results were kept apart 
to abridge evaluation.   
Within these topics sub-groups were made to evaluate common factors for change, 
whether it was a drug or an adverse effect, against one or several of these drugs, that 
had caused the clinician and patient to choose rituximab. More over the mere 
occurrence of adverse effects was registered from first administration and until the 7th 
injection. The attributes of the adverse effects were registered separately.  
 Reoccurrence of B-cells was tested before and after every treatment.  
 
Calculation	  and	  Analyses	  	  
All numeric data was plotted into SPSS Statistics version 22.0. Median and endpoints 
were calculated for the distribution of age, sex, disease duration, disease progression 
and severity. For SPMS, years in progress were also calculated.  
Ethics	  	  The	  patients	  when	  being	  registered	  to	  the	  Swedish	  MS-­‐register	  gave	  consent	  to	  the	  use	  and	  analysis	  of	  their	  journals	  and	  data.	  	  	  	  	  
	  
	  	  
 
 
	  
	  
	  	  	  
 
 
	  	  
Results	  
The median Disease Duration was overall longer in patients diagnosed with SPMS, a 
median of 19 years compared with compared to 12 and 11 years in median for RRMS 
and PPMS, respectively. Years in progression were for SPMS, a median of 6 years.  
 
The Number of Treatments was 3 (median) per patient, ranging from 1-10.  
Treatment Length varied from 3-74 months, with a median of 13 months. The PPMS-
group had a median time of 15 months, RRMS – 9months and SPMS – 13months.  
 
Table 2. Patients Demographics and disease duration.  
*Yr – years. **NA – not applicable. Within parenthesis – range and procentage. 
 
Change	  of	  treatment	  	  	  
The heterogeneous patient group all had different reasons for change of treatment, 
some with several combined reasons. The largest portion; 
MS-­‐type	   Number	  
of	  
patients	  	  
Gender	  	  
(f:m)	  
Age,	  yr*	  
Median	  
Duration,	  
yr	  Median	  	  
Years	  in	  
progress	  
(median)	  
All	  MS	   105	   58:47	   48	  
(17-­‐74)	  
14	  
(1-­‐44)	  
NA**	  
RRMS	   41	  (39%)	   28:13	   45	  
(17-­‐72)	  
12	  
(1-­‐32)	  
NA	  
SPMS	   41(39%)	   21:20	   50	  
(24-­‐71)	  
19	  
(6-­‐44)	  
6	  
(1-­‐24)	  
PPMS	   23(21.9%)	   9:14	   48	  
(26-­‐74)	  
11	  
(2-­‐21)	  
NA	  
-­‐ Out of 64 PMS-patients (SPMS and PPMS) 58 (90%) were offered Rituximab 
due to detectable disease progression under previous DMT. In the RRMS-
group 22 patients (56%) had relapses under previous DMT.  
Previous treatments were nataluzimab, beta-interferon, fingolimod, 
novantrone, mitoxantrone.  -­‐ 14 patients (34%) having RRMS had shown JC virus antibodies (JCV) under 
nataluzimab treatment and therefore also risk of PML. In PMS, 8 patients 
(12%) were at risk.  -­‐ 8 subjects (20%) with RRMS and 4 patients (6%) with PMS had shown AE’s 
against one or several previous DMT’s.  -­‐ 3 patients (7%) showed productions of NAB against either Beta-interferon or 
nataluzimab. In PMS the number was 2 patients (3%).    
 -­‐ 13 patients (12%) had cardiovascular or compliance problems, and therefore 
Rituximab was more suitable.  
 
Efficacy	  	  
Relapses the last two years – Amongst the RRMS patients 15 (36.6%) underwent 
episodes of relapses, 25 were in steady state and 3 had missing data.  
In the PMS-group, 14 patients (21.8%) had episodes of relapses, 44 in steady state 
(68.7%) and 6 with missing data.  
 
Out of the 41 patients having RRMS 4 (9.8%) had had episodes of neurological 
disturbances lasting for at least 24h, classified as relapses after RTX start. 3 patients 
had no record on this matter.  
In the equivalent PMS-group, 5 (7.8%) had relapses after start and a total of 9 had 
missing data.  
 
Table	  3.	  Collected	  Data	  –	  including:	  number	  of	  treatments,	  treatment	  length,	  EDSS-­‐values,	  MSSS-­‐values.	  In	  parenthisis	  are	  range	  and	  number	  of	  patients	  included.	  	  
 
There was an increase in EDSS when comparing parameters; EDSS at start and EDSS 
at extraction date (010814 and 010215). In RRMS patients went from a median of 
EDSS-score 3 to 3.5, with a range of 0-8.0. In PMS the median EDSS going into the 
study was 6 and at extraction date 6.5.  
 
The prognostic MSSS-score was instead decreased, from MSSS at start to MSSS at 
extraction date in both RRMS, -0.66 ranging 0.86-9.94 and in the PMS-group, -0.19 
	   Number	  of	  
treatments	  
Median	  
	  
Treatment	  
Length	  	  
Median	  
(months)	  
EDSS	  
One	  
year	  
prior	  	  
Median	  
EDSS	  
Start	  
Median	  
EDSS	  
*Date	  of	  
data	  
extraction	  
Median	  
	  
MSSS	  
Start	  
Median	  
MSSS	  
*Date	  of	  
data	  
extracti
on	  
Median	  
All	  
MS	  
3	  (median)	  
382	  (total)	  
(1-­‐10)	  
13	  
(3-­‐74)	  
4,5	  
(0-­‐8)	  
(n=84)	  
5	  
(0-­‐8.5)	  
(n=98)	  
6	  
(0-­‐8.5)	  
(n=87)	  
6.39	  
(0.86-­‐
9.83)	  
(n=98)	  
	  
6.33	  
(0.45-­‐
9.95)	  
(n=87)	  
RRMS	   3	  (median)	  
141	  (total)	  	  
9	  
(3-­‐74)	  
2,5	  
(0-­‐8)	  
(n=33)	  
3	  
(0-­‐8)	  
(n=39)	  
3.5	  
(0-­‐8)	  
(n=35)	  
4.79	  
(0.86-­‐
9.74)	  
(n=39)	  
4.13	  
(0.45-­‐
9.94)	  
(n=35)	  
SPMS	   3	  (median)	  
138	  (total)	  	  
13	  
(5-­‐41)	  
6,0	  
(2.5-­‐8)	  
(n=35)	  
6.5	  
(2.5-­‐
8.5)	  
(n=39)	  
6.25	  
(2.5-­‐8.5)	  
(n=34)	  
7.14	  
(1.43-­‐
9.57)	  
(n=39)	  
6.92	  
(1.43-­‐
9.81)	  
(n=34)	  
PPMS	   4	  (median)	  
89	  (total)	  
15	  
(3-­‐39)	  
6.0	  
(2-­‐8)	  
(n=16)	  
5.5	  	  
(1.5-­‐
8.5)	  
(n=20)	  
6	  	  
(0-­‐8.5)	  
(n=18)	  
7.2	  	  
(3.65-­‐
9.83)	  
(n=20)	  
7.19	  	  
(3.94-­‐
9.95)	  
(n=18)	  
	  *Date	  of	  extraction	  –	  on	  the	  010814	  and	  010215.	  Range	  showing	  within	  parenthesis	  as	  well	  as	  	  	  	  
ranging 1.43-9.95.  However it did not show statistical significance, in the entire 
group p= 0.077 and in the RRMS group p=0.052.  
 
New MRI lesions could be detected in 10 patients (24.4%) having RRMS and in 10 
patients (15.6%) having PPMS. A total of 31 patients had no record of MRI after 
start. 
Adverse	  Events	  	  
Adverse effects (AE) in correlation to administration of Rituximab. 52 patients 
(49.5%) felt AE’s in relation to the first injection.  
At the second injection the amount of patients feeling AE’s had dropped to 14 
(13.3%). Third injection, 10 patients were affected (9.6%).  
After third injections there were few reported AE’s.  
 
Common AE’s during injections included; Sensation of pressure over the chest, 
sensation of thickening in the gorge and tongue, with sometimes added itchiness.  
Flush in face and ears, headache, nausea and general fatigue was also common. Rare 
symptoms with fever and shivering also appeared.  
 
6 patients stopped the rituximab-treatment due to either subjective or objective AE’s.   
A total of 16 patients did stop their treatment. 6 Patients stopped due to adverse 
effects, 4 due to disease progression and 6 for unknown reasons.  
 
 
Reoccurrence of B-cell was noticeable in 5 cases (12.2%) in RRMS and 5 cases 
(7.8%) in PMS. 3 RRMS and 4 PMS patients had not been examined, most of which 
had either stopped their treatment all together before testing or due to relocation.  
 
 
 
Discussion	  	  
Indication and Efficacy 
Our retrospective study shows that a majority of this highly selected group started 
treatment on indication disease progression under previous treatment or for the 
RRMS-group, relapses under previous treatment. A great number of the subjects had 
undergone several treatments before choosing RTX as a last line of treatment. 
 
There is a median disability increase, shown through EDSS, in both RRMS and PMS 
whilst being under treatment of RTX. It is though difficult to estimate if RTX has 
given any effect on the disease activity. With no control group the efficacy could not 
be evaluated. 
However at baseline 36% of RRMS and 22% of PMS had relapses the last two years 
when compared with relapses after RTX start showed a decrease, where only 9.8% of 
RRMS and 7.8% of PMS reported relapses.  
  
It is also shown that the overall MSSS-score decreases, in both RRMS and under 
RTX treatment and that this may be an additional sign of treatment effect. However 
the score did not show statistical significance and since the MSSS score is based on a 
population with a majority not treated with immune-modulatory treatment it is 
debated if MSSS-score is representative for therapeutical effect, but since MSSS is 
predictive it may have importance.[74]  
 
Twenty patients (19%) had developed new MRI-lesions since beginning treatment 
with RTX. This illustrates that a minority of the patients had disease activity during 
the treatment period. The MRI data will be further analysed according to time from 
treatment start activity was seen. A treatment delay was observed in the OLYMPUS 
study, from treatment start to effect and it is possible that this could also be the case in 
this study and could partly explain the EDSS increase and MRI-lesions. [7] 
 
Is rituximab safe?  
Despite the fact that 49.5% of the study group experienced adverse events (AE) upon 
first injection none of these AE’s were life threatening. In addition, upon the second 
injection only 13.3% had AE’s and at the subsequent infusions even less, 9.6%. Most 
AE were infusion related. 
As has been concluded in other studies treatment with RTX is correlated with an 
increased risk of adverse effects but not serious adverse events.[75] It has also 
previously been shown that AE’s lessen with subsequent infusions, which also was 
the case in this study, with AE being uncommon after third dose.  
It is natural to assume that the cytokine-release upon lysis of B-cells, which is the 
greatest upon first infusions, decrease in line with lesser amount of circulating B-
cells. [76]  
 
RTX should be considered safe when used properly, never the less we can only 
account for a median treatment time of 13 months. Long-term effects have not yet 
been evaluated. We do however have a range of 3-74 months in treatment length, 
which then includes 21 patients (20%) having been under treatment  for more then 
two years without unpredicted AE. More studies evaluating AE’s on larger 
populations and during longer periods of time is still needed.  
 
The risk of JCV and PML in MS-patients treated with RTX has not yet been tested, 
but the incidence in Rheumatoid Arthritis patients treated with RTX is 1/25000. [77] 
Comparing this with the incidence of PML when being under (monoclonal antibody) 
nataluzimab treatment, 11/1000, shows a much lower risk. (Biogen – tysabri fact 
sheet). In studies of nataluzimab it has been observed that some adverse events such 
as PML appear more frequently after two full years of treatment. [75] So far no 
indications are seen that this problem is the same for RTX.   
 
A total of 16 patients stopped the treatment, 6 due to AE, 4 due to treatment failure 
shown on MRI and/or clinically. 6 stopped due to relocations or unknown reasons.  
A dropout rate of 15% should be considered low and is in line with other treatment on 
label for MS, especially when taking into account the different reasons for stopping 
treatment. [78, 79] 
 
Five RRMS and five PMS patients had reoccurrence of B-cells whilst being under 
RTX treatment. It would could be valued if reocurrence would mirror a more 
aggressive disease or lack of treatment response. We could not find any correlation 
between this phenomenon and disease activity. The role of this population of B-cells 
in the disease process is obscure and needs to be investigated further.  
 
 
 
Strengths and weaknesses  
The group itself is challenging to analyze since they’ve shown to be particularly 
difficult to treat, hence being patients trying a second or last line of treatment 
available. Therefor the study results of progression rate, treatment effect, adverse 
effect can and will only be applicable to a small group of people. A sufficiently 
qualified control group would have been difficult to find, none the less as is said this 
is a group that needs more attention and is in need of sustainable treatment.  
 
Missing data for several patients throughout the study.  
Due to the character of the retrospective study, it was preferable to extract the patient 
data so that as many as possible would be included. In doing so some patients had not 
yet acquired certain information, e.g. MRI-scans or B-cell reoccurrence test results. 
This can only explain in part missing data. 
 
When retrieving information from medical charts and registers there can be bias in the 
chart itself, when transferring data and handling data.  
 
With an average of one year of treatment, outcomes and AE could properly be 
addressed. By using both journals and the MS-reg we were able to, to some extent, 
substantiation information.  
 
Use and Future 
To our knowledge a retrospective study of the outcome for patients, in Gothenburg, 
Sweden, treated for MS with RTX has never before been done.  
In order to have a better perspective of the prescription of Rituximab in Multiple 
Sclerosis, this study is a small step in obtaining increased knowledge.  
Adding knowledge to a treatment form where not even the pathophysiology is clearly 
understood can help in making this treatment safer and better.  
Finding patterns, standardizing and creating criteria on which physicians can seek 
guidance can be of help.  
 
There are ongoing studies towards usage of Rituximab as a generica, called 
Ocreluzimab, and therefore it is acknowledged that anti-CD20 antibodies has a place 
and a purpose in the treatment of MS. However with Oclreluximab on the horizon, 
questions arise concerning the future off-label use of Rituximab.  
 
Conclusion	  	  
RTX was used as treatment primarily as a last line of treatment after having disease 
activity in previous treatments. RTX was well tolerated with no severe AE. RTX had 
no obvious effect on EDSS progression but decreased relapse rate and MSSS, though 
not statistically significant (p=0,077), could indicate a beneficial effect in both RRMS 
and PMS. 	  	  	  	  
	  
	  	  	  
Polulärvetenskaplig	  sammanfattig	  (Swedish)	  	  
I denna studie tittade vi på multipel skleros (MS) -patienter som står under behandling 
av det oregistrerade läkemedlet rituximab. Det finns idag teorier om att andra delar av 
immunförsvaret är delaktiga i MS-sjukdomen än vad man tidigare trott. Rituximab är 
ett läkemedel som angriper en viss sorts celler, B-celler, som är delaktiga i 
immunförsvaret. Detta läkemedel har visat effekt speciellt på en subgrupp patienter 
med MS i två mindre förstudier.  
Vi inhämtade data och information från MS-registret och patientjournaler. Patienterna 
som fick rituximab hade till största del haft sjukdomsaktivitet, exv anfall, i sin MS när 
det stått på annan behandling och därför valt att byta. Andra orsaker var relaterade till 
allergi och livshotande följdtillstånd.  
Parametrar så som funktionsnedsättningsskalan, EDSS, visade en ökad invaliditet från 
start till i genomsnitt ett års behandling, men den prognostiska skalan MSSS visade 
förbättrad prognos. Vi såg även minskad sjukdoms-attacker jämfört med tidigare. 
Dock visar dessa resultat bara en del av bilden då vi inte har någon kontrollgrupp.   
Vi såg även att läkemedlet var väl tolererat i patientgruppen. Patienterna fick 
biverkningar, men dessa var ej allvarliga och var uppkom främst vid första 
behandlingstillfället. 
En uppföljande studie på patienter som behandlas med rituximab har inte tidigare 
gjorts och detta är ett litet steg i att få bättre insikt i biverkningar, anledningar till 
insättande av läkemedel och att se den effekt som behandlingen ger.  
Med liknande preparat på väg ut på marknaden så är det än viktigare att hitta rätt 
indikationer och vad biverkningsprofilen är, för att rätt patienter ska få behandlingen.  
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